Literature DB >> 8148401

Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients.

S Kondo1, M Asano, K Matsuo, I Ohmori, H Suzuki.   

Abstract

We developed an enzyme-linked immunosorbent assay (ELISA) for vascular endothelial growth factor/vascular permeability factor (VEGF/VPF). The assay revealed that VEGF/VPF levels in the sera of mice were significantly increased from undetectable level by s.c. transplantation with a solid tumor. We also measured VEGF/VPF levels in serum specimens obtained from cancer patients with several types of cancers. VEGF/VPF levels in the sera from cancer patients were significantly higher than those in the sera from the individuals with no sign of cancer.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8148401     DOI： 10.1016/0167-4889(94)90016-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  41 in total

1.  Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.

Authors:  Y X Yin; F Shen; H Pei; Y Ding; Hua Zhao; Min Zhao; Q Chen
Journal:  Tumour Biol       Date:  2012-05-30

Review 2.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  CD4+VEGFR1(HIGH) T cell as a novel Treg subset regulates inflammatory bowel disease in lymphopenic mice.

Authors:  Jin-Young Shin; Il-Hee Yoon; Jong-Hyung Lim; Jun-Seop Shin; Hye-Young Nam; Yong-Hee Kim; Hyoung-Soo Cho; So-Hee Hong; Jung-Sik Kim; Won-Woo Lee; Chung-Gyu Park
Journal:  Cell Mol Immunol       Date:  2015-07-27       Impact factor: 11.530

4.  Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis.

Authors:  Zhongdong Hu; Ying Wang; Fuqiang Huang; Rongrong Chen; Chunjia Li; Fang Wang; June Goto; David J Kwiatkowski; Joanna Wdzieczak-Bakala; Pengfei Tu; Jianmiao Liu; Xiaojun Zha; Hongbing Zhang
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

Review 5.  Angiogenic factors as tumor markers.

Authors:  M Nguyen
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 6.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

7.  Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis?

Authors:  J Dunst; S Pigorsch; G Hänsgen; I Hintner; C Lautenschläger; A Becker
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

8.  Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.

Authors:  Yuhui Huang; Xiaolan Chen; Mikhail M Dikov; Sergey V Novitskiy; Claudio A Mosse; Li Yang; David P Carbone
Journal:  Blood       Date:  2007-03-21       Impact factor: 22.113

9.  Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.

Authors:  Xin Li; Gan-Sheng Feng; Chuan-Sheng Zheng; Chen-Kai Zhuo; Xi Liu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

10.  Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro.

Authors:  Y Sawaji; T Sato; A Takeuchi; M Hirata; A Ito
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.